Psyllium and glucomannan—two gel-forming soluble fibers with complementary physicochemical profiles—modulate metabolic health through luminal viscosity, bile acid sequestration, short-chain fatty acid (SCFA) production, epithelial tight-junction support, and L-cell GLP-1 signaling. Psyllium carries the strongest clinical evidence for LDL reduction, glycemic modulation, and stool normalization, while glucomannan's exceptional water-holding capacity adds satiety and lipid-lowering potential. A novel framing here concerns GLP-1 receptor agonist (GLP-1RA) therapy: appetite suppression, reduced meal volume, and constipation induced by semaglutide-class drugs create a compounding fiber deficit that may starve colonic microbiota of fermentable substrate.
This review arrives at a clinically timely moment. GLP-1RA prescriptions have surged globally, yet the downstream nutritional consequences—reduced fermentation, diminished SCFA output, altered gut motility—are rarely addressed in practice. Fiber depletion during GLP-1RA therapy could blunt the very microbiome-incretin feedback loops these drugs rely on. The paper's hypothesis that fiber deficiency during GLP-1RA use might affect pain and mood outcomes is speculative but mechanistically plausible given SCFA-enteric nervous system crosstalk. Critical caveats: this is a narrative review, not a meta-analysis or original trial, so it cannot establish causality or rank effect sizes. Psyllium's evidence base is substantially more robust than glucomannan's. Still, the GLP-1RA–fiber interaction angle is underexplored and clinically actionable: the incremental insight here is real, even if the paradigm remains hypothesis-level.
